MX2014003983A - Metodo para diagnosticar la enfermedad de alzheimer (ad). - Google Patents

Metodo para diagnosticar la enfermedad de alzheimer (ad).

Info

Publication number
MX2014003983A
MX2014003983A MX2014003983A MX2014003983A MX2014003983A MX 2014003983 A MX2014003983 A MX 2014003983A MX 2014003983 A MX2014003983 A MX 2014003983A MX 2014003983 A MX2014003983 A MX 2014003983A MX 2014003983 A MX2014003983 A MX 2014003983A
Authority
MX
Mexico
Prior art keywords
specific antibodies
aggregates
disease
sample
diagnosing alzheimer
Prior art date
Application number
MX2014003983A
Other languages
English (en)
Spanish (es)
Inventor
Walter Schmidt
Frank Mattner
Günther Staffler
Andreas Mairhofer
Martina Lutterova
Achim Schneeberger
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of MX2014003983A publication Critical patent/MX2014003983A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Sampling And Sample Adjustment (AREA)
MX2014003983A 2011-10-04 2012-09-20 Metodo para diagnosticar la enfermedad de alzheimer (ad). MX2014003983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11183842.1A EP2579042B1 (en) 2011-10-04 2011-10-04 Method for detecting Aß-specific antibodies in a biological sample
PCT/EP2012/068493 WO2013050248A1 (en) 2011-10-04 2012-09-20 Method for diagnosing alzheimer's disease (ad)

Publications (1)

Publication Number Publication Date
MX2014003983A true MX2014003983A (es) 2014-05-07

Family

ID=46888451

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003983A MX2014003983A (es) 2011-10-04 2012-09-20 Metodo para diagnosticar la enfermedad de alzheimer (ad).
MX2014003984A MX2014003984A (es) 2011-10-04 2012-09-20 Metodo para detectar anticuerpos a-beta especificos en una muestra biologica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014003984A MX2014003984A (es) 2011-10-04 2012-09-20 Metodo para detectar anticuerpos a-beta especificos en una muestra biologica.

Country Status (23)

Country Link
US (2) US9625459B2 (pl)
EP (3) EP2579042B1 (pl)
JP (2) JP6162127B2 (pl)
KR (2) KR20140073568A (pl)
CN (2) CN103842824A (pl)
AR (1) AR088108A1 (pl)
AU (2) AU2012320766B2 (pl)
BR (2) BR112014008088A2 (pl)
CA (2) CA2850840A1 (pl)
CY (1) CY1115624T1 (pl)
DK (2) DK2579042T3 (pl)
ES (2) ES2496341T3 (pl)
HR (1) HRP20140937T1 (pl)
IL (2) IL231057A0 (pl)
MX (2) MX2014003983A (pl)
PL (2) PL2579042T3 (pl)
PT (1) PT2579042E (pl)
RS (1) RS53496B1 (pl)
RU (2) RU2014117671A (pl)
SG (2) SG11201400223SA (pl)
SI (1) SI2579042T1 (pl)
SM (1) SMT201400145B (pl)
WO (2) WO2013050248A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2787347A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
EP2787349A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
KR101658620B1 (ko) * 2014-12-02 2016-09-23 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
KR20170108203A (ko) 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
KR101871895B1 (ko) * 2016-04-20 2018-06-28 한국과학기술연구원 응집 단백질의 고감도 광 산화 증폭 면역 분석을 통한 체액기반의 퇴행성 신경질환 진단 방법
EP3242134A1 (en) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
KR101989383B1 (ko) * 2017-04-04 2019-06-14 조선대학교산학협력단 알츠하이머성 치매의 조기진단을 위한 펩타이드 프로브
KR102108171B1 (ko) * 2018-08-27 2020-05-08 광주과학기술원 알츠하이머성 치매 진단용 펩타이드 바이오마커
WO2020045962A1 (ko) * 2018-08-27 2020-03-05 광주과학기술원 알츠하이머성 치매 진단용 펩타이드 바이오마커
CN113063949B (zh) * 2021-03-23 2024-11-15 中国医学科学院输血研究所 一种血浆中特异性IgM抗体的定量测定方法
CN113075398A (zh) * 2021-03-23 2021-07-06 中国医学科学院输血研究所 一种血浆中特异性IgG抗体的定量测定方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
WO1996012544A1 (en) 1994-10-19 1996-05-02 The General Hospital Corporation A DIAGNOSTIC ASSAY FOR ALZHEIMER'S DISEASE: ASSESSMENT OF Aβ ABNORMALITIES
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
US20060188951A1 (en) 2003-02-24 2006-08-24 In Hee Mook Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer's disease using same
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
DE102005006217B4 (de) * 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
JP4937143B2 (ja) * 2005-03-05 2012-05-23 アボット ゲーエムベーハー ウント カンパニー カーゲー 非拡散性球状Aβ(X−38..43)オリゴマー構造エピトープに対して特異性を有する自己抗体を検出する方法
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
SG10201404801YA (en) * 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
JP2010515717A (ja) * 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
WO2009051599A1 (en) * 2007-10-19 2009-04-23 The Regents Of The University Of California Use of biomarkers of alzheimer's disease for diagnostic tests and drug screening
US7771957B2 (en) * 2007-10-19 2010-08-10 The Regents Of The University Of California Method for diagnosing alzheimer's disease
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
RU2011100127A (ru) 2008-06-12 2012-07-20 Аффирис Аг (At) Соединение, содержащее пептид, для лечения симптомов болезни паркинсона
CA2753586A1 (en) * 2009-02-24 2010-09-02 Winton G. Gibbons Detection of complexes of tau and amyloid
WO2010128139A1 (en) 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Aβを標的とする免疫療法のPETモニタリング

Also Published As

Publication number Publication date
AU2012320767A1 (en) 2014-03-13
AR088108A1 (es) 2014-05-07
EP2764368A1 (en) 2014-08-13
AU2012320766A1 (en) 2014-03-13
IL231620A0 (en) 2014-05-28
JP6162127B2 (ja) 2017-07-12
HRP20140937T1 (hr) 2014-12-05
SG11201400223SA (en) 2014-05-29
DK2764367T3 (en) 2018-10-29
MX2014003984A (es) 2014-05-07
EP2764367B1 (en) 2018-07-25
AU2012320766B2 (en) 2017-09-21
JP2014529088A (ja) 2014-10-30
ES2692185T3 (es) 2018-11-30
PL2579042T3 (pl) 2014-12-31
RS53496B1 (sr) 2015-02-27
BR112014008088A2 (pt) 2017-04-18
BR112014008089A2 (pt) 2017-04-18
KR20140073568A (ko) 2014-06-16
SG11201400229XA (en) 2014-05-29
SMT201400145B (it) 2014-11-10
EP2579042B1 (en) 2014-07-09
EP2579042A1 (en) 2013-04-10
DK2579042T3 (da) 2014-07-21
SI2579042T1 (sl) 2014-09-30
JP2014529087A (ja) 2014-10-30
WO2013050249A1 (en) 2013-04-11
IL231057A0 (en) 2014-03-31
US9625459B2 (en) 2017-04-18
RU2014117671A (ru) 2015-11-10
CY1115624T1 (el) 2017-01-04
CN103842825A (zh) 2014-06-04
US20140242727A1 (en) 2014-08-28
HK1178601A1 (en) 2013-09-13
CA2850840A1 (en) 2013-04-11
KR20140069346A (ko) 2014-06-09
PL2764367T3 (pl) 2019-04-30
RU2014117677A (ru) 2015-11-10
EP2764367A1 (en) 2014-08-13
US20140234877A1 (en) 2014-08-21
CN103842824A (zh) 2014-06-04
ES2496341T3 (es) 2014-09-18
PT2579042E (pt) 2014-09-09
CN103842825B (zh) 2016-04-20
WO2013050248A1 (en) 2013-04-11
CA2850843A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
MX2014003983A (es) Metodo para diagnosticar la enfermedad de alzheimer (ad).
WO2009037659A3 (en) Magnetic detection of small entities
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
MA34927B1 (fr) Anticorps anti-cea
WO2011109372A8 (en) Ultra-sensitive detection of molecules using dual detection methods
MX344935B (es) Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
EP3009454A3 (en) Antibodies specific to cadherin-17
WO2013165615A3 (en) Methods, systems, and devices for detecting and identifying microorganisms in microbiological culture samples
AU2012356133A8 (en) A rapid quantitative assay to measure CFTR function in a primary intestinal culture model
WO2014068408A3 (en) Aptamers and uses thereof
TN2014000120A1 (en) Cd27l antigen binding proteins
MX2008006945A (es) Biosensor de deteccion de patogeno.
WO2011088014A3 (en) Systems and methods for counting cells and biomolecules
NZ602220A (en) Antibodies with ph dependent antigen binding
EA201390638A8 (ru) Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения
MX347247B (es) Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad.
WO2013055142A3 (ko) 두 종 입자를 이용한 다기능 생체물질 접합체의 제조방법 및 이로부터 제조된 다기능 생체물질 접합체
EP2631649A8 (en) Method and device for the rapid diagnosis of diseases in faecal samples
WO2014138132A3 (en) Multi-analyte assay
WO2013072842A8 (en) Long rigid spacers to enhance binding kinetics in immunoassays
EP3320900A3 (en) Marker for determination of sensitivity to anticancer agent
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011143574A3 (en) Plasma biomarkers for diagnosis of alzheimer's disease
WO2014004609A3 (en) Rapid assays for t-cell activation by rna measurements using flow cytometry
SG10201906124XA (en) Foetal nucleated red blood cell detection

Legal Events

Date Code Title Description
FA Abandonment or withdrawal